Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

10.5 -1.5

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.02

Max

10.67

Schlüsselkennzahlen
By Trading Economics
Einkommen	-4.3M -18M
EPS	-0.19
Angestellte	37
EBITDA	-5.3M -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+193.53% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-313M 812M
Vorheriger Eröffnungskurs	12
Vorheriger Schlusskurs	10.5

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Okt. 2026, 23:56 UTC

Daily Journal Corp shares advanced in after-market trading, settling at a notable gain.

22. Okt. 2026, 23:56 UTC

Zimmer Biomet Holdings, Inc. shares declined modestly in after-market trading, retracing from a brief peak earlier in the session.

22. Okt. 2026, 23:56 UTC

PENN Entertainment Inc is trading higher in after-market hours, significantly above its 20-day moving average and near the upper end of its one-month trading range.

22. Okt. 2026, 23:56 UTC

XP Inc shares are experiencing a modest decline in after-market hours, marking three consecutive daily decreases while remaining above their 20-day moving average.

22. Okt. 2026, 23:56 UTC

Correlated Moves

Routine after-market trading shows little change since Thursday's close.

22. Okt. 2026, 23:56 UTC

CRISPR Therapeutics AG is trading slightly higher in after-market hours, reflecting a modest increase since Thursday's close while remaining below its 20-day moving average.

22. Okt. 2026, 23:56 UTC

Hess Midstream LP is trading modestly higher in after-market hours, recovering from an earlier low while remaining below its 20-day moving average.

22. Okt. 2026, 23:56 UTC

Old Dominion Freight Line Inc is trading roughly flat in after-market hours, maintaining a position just above its Thursday close.

22. Okt. 2026, 23:56 UTC

Agree Realty Corp shares are trading lower in after-market hours, with a cumulative return declining from a low, remaining above its 20-day moving average.

22. Okt. 2026, 23:56 UTC

McCormick & Company Inc shares are trading modestly lower in after-market hours, declining from earlier in the session but remaining above its 20-day moving average.

22. Okt. 2026, 23:52 UTC

Macro News

Natural gas prices are higher amid rising tensions in the Middle East, with concerns about military conflicts potentially impacting global oil and gas markets.

22. Okt. 2026, 23:52 UTC

Japan's Inflation Rate Rises to 2.1% in September, Aligning with Expectations and Indicating Economic Stability

22. Okt. 2026, 23:52 UTC

Japan's Core Inflation Rate Rises to 2.1%, Meeting Expectations and Indicating Economic Stability Amid Global Pressures

22. Okt. 2026, 23:52 UTC

UK Consumer Confidence Plummets to -24.0, Signaling Economic Pessimism Amid Rising Inflation and Geopolitical Tensions

22. Okt. 2026, 23:52 UTC

U.S. Consumer Sentiment Expected to Decline to 46.3 Amid Economic Concerns Ahead of Midterm Elections

22. Okt. 2026, 23:52 UTC

Australia's Inflation Rate Release on October 28 Sparks Market Speculation of Interest Rate Hikes Amid Rising Global Pressures.

22. Okt. 2026, 23:52 UTC

Australia's Core Inflation Rate Expected to Rise, Heightening Speculation of November Interest Rate Hike Amidst Oil Price Pressures.

22. Okt. 2026, 23:52 UTC

Japan's Industrial Production Data Release on October 29 Faces Cautious Market Sentiment Amid Recent Declines and Economic Uncertainties.

22. Okt. 2026, 23:52 UTC

Japan's Retail Sales Data Release on October 29 Sparks Caution Amidst Economic Slowdown and Trade Deficits.

22. Okt. 2026, 23:52 UTC

Social Media

Walmart Inc shares traded higher in after-market hours, gaining ground since Thursday's close, with users on X discussing potential upward movement based on chart patterns.

22. Okt. 2026, 23:51 UTC

Regeneron Pharmaceuticals Inc is trading higher in after-market hours, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

22. Okt. 2026, 23:51 UTC

DTE Energy Co shares are trading modestly lower in after-market hours, reflecting a slight decline since Thursday's close while remaining above the 20-day moving average.

22. Okt. 2026, 23:51 UTC

In after-market trading, Church & Dwight Co Inc is modestly lower, retracing from earlier gains and declining below Thursday's close.

22. Okt. 2026, 23:51 UTC

Penumbra Inc shares are trading modestly higher in after-market hours, recovering from an earlier dip and reaching a high point above its 20-day moving average.

22. Okt. 2026, 23:51 UTC

Figs Inc shares advanced in after-market trading, continuing an upward trajectory since Thursday's close and finishing higher for five consecutive sessions.

22. Okt. 2026, 23:51 UTC

Motorola Solutions Inc. is trading modestly higher in after-market hours, marking four consecutive daily gains and remaining above its 20-day moving average.

22. Okt. 2026, 23:51 UTC

Sirius XM Holdings Inc is trading modestly higher in after-market hours, recovering from a low point immediately after the market closed.

22. Okt. 2026, 23:51 UTC

Align Technology Inc is trading modestly lower in after-market hours, having dipped to its lowest point.

22. Okt. 2026, 23:51 UTC

Correlated Moves

American Superconductor Corp shares are trading lower in after-market hours, marking their lowest point since Thursday's close following a brief peak.

22. Okt. 2026, 23:51 UTC

Johnson & Johnson shares traded modestly lower during after-market hours on Thursday, breaking a recent trend of higher daily closes.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

193.53% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD 193.53%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.